Aptar Pharma announces development and license agreement with BD to bring a novel autoinjector to market

AptarGroup is a leading global supplier of a broad range of innovative dispensing solutions for the beauty, personal care, home care, prescription drug, consumer healthcare, injectables, food and beverage markets

Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, announced the signing of an exclusive development and license agreement with BD (Becton, Dickinson and Company) to jointly develop a novel autoinjector using Aptar Pharma’s high-performance, two-step autoinjector technology and prefillable syringes from BD.

Autoinjectors are designed to be used safely and conveniently by patients for self-injection in a non-medical environment, such as the home or office. Aptar Pharma has utilised feedback obtained from its market research involving patients and healthcare professionals to create and optimise a compact device capable of delivering high viscosity drugs including some of the newest biologics.

The autoinjector technology was specifically designed around the BD Neopak 1mL long glass prefillable syringe or the BD Hypak for Biotech 1mL long glass prefillable syringe to optimise system robustness and performance.

Under the agreement, BD, a leading global medical technology company with a broad portfolio of innovative drug delivery systems, and Aptar Pharma will jointly develop Aptar Pharma’s autoinjector technology platform using BD’s expertise in prefillable syringes and self-injection technologies combined with Aptar Pharma’s innovation and quality by design (QbD) expertise.

This unique two-step autoinjector will be exclusively commercialised by BD as a part of their portfolio of autoinjectors.

'We are pleased to be extending our relationship with BD from pharmaceutical elastomer components supplier to now also include the joint development of an autoinjector system. The key advantages of this platform hinge on the ease of use, ergonomic shape, improved feedback indicators, and the ability to handle viscous drug formulations,' said Salim Haffar, President of Aptar Pharma.

Companies